FDA approves first COVID-19 drug: antiviral remdesivir

by on

The drug cut the time to recovery by five days—from 15 days to 10 on average—in a large study led by the U.S. National Institutes of Health.

The drug cut the time to recovery by five days—from 15 days to 10 on average—in a large study led by the U.S. National Institutes of Health.

VA:F [1.9.7_1111]
Rating: 0.0/10 (0 votes cast)
VA:F [1.9.7_1111]
Rating: 0 (from 0 votes)

Leave a Comment

Previous post:

Next post: